Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Joseph‐Mathurin, Nelly , Li, Yan , McCullough, Austin , Hofmann, Carsten, Wojtowicz, Jakub , Park, Ethan, Wang, Guoqiao , Preboske, Gregory M., Gordon, Brian A. , Chen, Charles D., Flores, Shaney , Aggarwal, Neelum T. , Berman, Sarah , Bird, Thomas D., Borowski, Bret, Chhatwal, Jasmeer P. , Clarnette, Roger, Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Gauthier, Serge , Hassenstab, Jason , Hobbs, Diana A. , Holdridge, Karen C. , Hornbeck, Russ C. , Jiménez‐Velázquez, Ivonne Z. , Klein, Gregory , Xiong, Chengjie , Mancini, Michele , McKay, Nicole S. , Mummery, Catherine J. , Ringman, John M. , Snider, B. Joy, Suzuki, Kazushi , Yaari, R. , Perrin, Richard J. , Bateman, Randall J. , Salloway, Stephen , Clifford, David B., Unit, For the Dominantly Inherited Alzheimer Network Trials, Wang, Qing , Gordon, Brian A , Chen, Charles D , Jucker, Mathias , Ringman, John M , Salloway, Steve , Benzinger, Tammie L S , Bateman, Randall J , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Berman, Sarah , Llibre‐Guerra, Jorge J. , Li, Yan, Wáng, Qīng , Black, Sandra E. , Brooks, William S. , Cruchaga, Carlos , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jack, Clifford R. , Masellis, Mario , Shimada, Hiroyuki , Wallon, David , Xiong, Chengjie , McDade, Eric , Benzinger, Tammie L.S. , Unit, For the Dominantly Inherited Alzheimer Network Trials

Mayo Clinic

Annals of Neurology | September 24, 2022 | Volume: 92 | Issue: 5 | Pages: 729-744

10.1002/ana.26511 | PMID 36151869 Get It

ObjectiveTo determine the characteristics of participants with amyloid‐related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD).Methods142 DIAD mutation carriers received either gantenerumab SC (n = 52), solanezumab IV (n = 50), or placebo (n = 40). Participants underwent assessments with the Clinical Dementia Rating® (CDR®), neuropsychological testing, CSF biomarkers, β‐amyloid positron emission tomography (PET), and magnetic resonance imaging (MRI) to monitor ARIA. Cross‐sectional and longitudinal analyses evaluated potential ARIA‐related risk factors.ResultsEleven participants developed ARIA‐E, including 3 with mild symptoms. No ARIA‐E was reported under solanezumab while gantenerumab was associated with ARIA‐E compared to placebo (odds ratio [OR] = 9.1, confidence interval [CI][1.2, 412.3]; p = 0.021). Under gantenerumab, APOE‐ɛ4 carriers were more likely to develop ARIA‐E (OR = 5.0, CI[1.0, 30.4]; p = 0.055), as were individuals with microhemorrhage at baseline (OR = 13.7, CI[1.2, 163.2]; p = 0.039). No ARIA‐E was observed at the initial 225 mg/month gantenerumab dose, and most cases were observed at doses >675 mg. At first ARIA‐E occurrence, all ARIA‐E participants were amyloid‐PET+, 60% were CDR >0, 60% were past their estimated year to symptom onset, and 60% had also incident ARIA‐H. Most ARIA‐E radiologically resolved after dose adjustment and developing ARIA‐E did not significantly increase odds of trial discontinuation. ARIA‐E was more frequently observed in the occipital lobe (90%). ARIA‐E severity was associated with age at time of ARIA‐E.InterpretationIn DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA‐E risk, with additional risk for individuals APOE‐ɛ4(+) or with microhemorrhage. ARIA‐E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729–744
Correlation of the Modified Japanese Orthopedic Association With Functional and Quality-of-Life Outcomes After Surgery for Degenerative Cervical Myelopathy: A Quality Outcomes Database Study
Yee, Timothy J., Upadhyaya, Cheerag D., Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Turner, Jay D. , Knightly, Jack, Fu, Kai-Ming, Foley, Kevin T. , Tumialán, Luis M. , Shaffrey, Mark E., Bydon, Mohamad , Mummaneni, Praveen V. , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Asher, Anthony L. , Shaffrey, Christopher I. , Gottfried, Oren N., Than, Khoi D. , Wang, Michael Y. , Buchholz, Avery L., Haid, Regis W., Park, Paul

Mayo Clinic

Neurosurgery | September 23, 2022 | Volume: 91 | Issue: 6 | Pages: 952-960

10.1227/neu.0000000000002161 | PMID 36149088 Get It

BACKGROUND: The modified Japanese Orthopedic Association (mJOA) score is a widely used and validated metric for assessing severity of myelopathy. Its relationship to functional and quality-of-life outcomes after surgery has not been fully described. OBJECTIVE: To quantify the association of the mJOA with the Neck Disability Index (NDI) and EuroQol-5 Dimension (EQ-5D) after surgery for degenerative cervical myelopathy. METHODS: The cervical module of the prospectively enrolled Quality Outcomes Database was queried retrospectively for adult patients who underwent single-stage degenerative cervical myelopathy surgery. The mJOA score, NDI, and EQ-5D were assessed preoperatively and 3 and 12 months postoperatively. Improvement in mJOA was used as the independent variable in univariate and multivariable linear and logistic regression models. RESULTS: Across 14 centers, 1121 patients were identified, mean age 60.6 ± 11.8 years, and 52.5% male. Anterior-only operations were performed in 772 patients (68.9%). By univariate linear regression, improvements in mJOA were associated with improvements in NDI and EQ-5D at 3 and 12 months postoperatively (all P < .0001) and with improvements in the 10 NDI items individually. These findings were similar in multivariable regression incorporating potential confounders. The Pearson correlation coefficients for changes in mJOA with changes in NDI were −0.31 and −0.38 at 3 and 12 months postoperatively. The Pearson correlation coefficients for changes in mJOA with changes in EQ-5D were 0.29 and 0.34 at 3 and 12 months. CONCLUSION: Improvements in mJOA correlated weakly with improvements in NDI and EQ-5D, suggesting that changes in mJOA may not be a suitable proxy for functional and quality-of-life outcomes.
Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
Sicotte, Hugues , Qin, Sisi , Dehm, Scott M. , Bhargava, Vipul , Gormley, Michael , Tan, Winston , Hillman, David W. , Li, Ying , Vedell, Peter T. , Carlson, Rachel E. , Bryce, Alan H. , Jimenez, Raphael E., Weinshilboum, Richard M. , Wang, Liewei , Kalari, Krishna R , Qin, Sisi , Dehm, Scott M , Bhargava, Vipul , Gormley, Michael , Tan, Winston , Sinnwell, Jason P , Hillman, David W , Li, Ying , Vedell, Peter T , Carlson, Rachel E , Bryce, Alan H , Jimenez, Raphael E , Weinshilboum, Richard M. , Kohli, Manish , Wang, Liewei , Kalari, Krishna R. , Sinnwell, Jason P. , Kohli, Manish

Mayo Clinic

Molecular Cancer Research | September 22, 2022 | Volume: 20 | Issue: 12 | Pages: 1739-1750

10.1158/1541-7786.mcr-22-0099 | PMID 36135372 Get It

Abstract We identified resistance mechanisms to abiraterone acetate/prednisone (AA/P) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study. We analyzed whole-exome sequencing (WES) and RNA-sequencing data from 83 patients with metastatic biopsies before (V1) and after 12 weeks of AA/P treatment (V2). Resistance was determined by time to treatment change (TTTC). At V2, 18 and 11 of 58 patients had either short-term (median 3.6 months; range 1.4–4.5) or long-term (median 29 months; range 23.5–41.7) responses, respectively. Nonresponders had low expression of TGFBR3 and increased activation of the Wnt pathway, cell cycle, upregulation of AR variants, both pre- and posttreatment, with further deletion of AR inhibitor CDK11B posttreatment. Deletion of androgen processing genes, HSD17B11, CYP19A1 were observed in nonresponders posttreatment. Genes involved in cell cycle, DNA repair, Wnt-signaling, and Aurora kinase pathways were differentially expressed between the responder and non-responder at V2. Activation of Wnt signaling in nonresponder and deactivation of MYC or its target genes in responders was detected via SCN loss, somatic mutations, and transcriptomics. Upregulation of genes in the AURKA pathway are consistent with the activation of MYC regulated genes in nonresponders. Several genes in the AKT1 axis had increased mutation rate in nonresponders. We also found evidence of resistance via PDCD1 overexpression in responders. Implications: Finally, we identified candidates drugs to reverse AA/P resistance: topoisomerase inhibitors and drugs targeting the cell cycle via the MYC/AURKA/AURKB/TOP2A and/or PI3K_AKT_MTOR pathways.
CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer
Wei, Ting , Ding, Donglin , Zhang, Jianong , He, Housheng Hansen , Wang, Liguo , Sun, Rui , Wei, Ting , He, Housheng Hansen , Wang, Liguo , Sun, Rui , Chen, Sujun , Huang, Haojie , Sun, Rui

Mayo Clinic

Proceedings of the National Academy of Sciences | September 21, 2022 | Volume: 119 | Issue: 39 | Pages: No page available

10.1073/pnas.2205509119 | PMID 36129942 Get It

Androgen receptor (AR) messenger RNA (mRNA) alternative splicing variants (AR-Vs) are implicated in castration-resistant progression of prostate cancer (PCa), although the molecular mechanism underlying the genesis of AR-Vs remains poorly understood. The CDK12 gene is often deleted or mutated in PCa and CDK12 deficiency is known to cause homologous recombination repair gene alteration or BRCAness via alternative polyadenylation (APA). Here, we demonstrate that pharmacological inhibition or genetic inactivation of CDK12 induces AR gene intronic (intron 3) polyadenylation (IPA) usage, AR-V expression, and PCa cell resistance to the antiandrogen enzalutamide (ENZ). We further show that AR binds to the CCNK gene promoter and up-regulates CYCLIN K expression. In contrast, ENZ decreases AR occupancy at the CCNK gene promoter and suppresses CYCLIN K expression. Similar to the effect of the CDK12 inhibitor, CYCLIN K degrader or ENZ treatment promotes AR gene IPA usage, AR-V expression, and ENZ-resistant growth of PCa cells. Importantly, we show that targeting BRCAness induced by CYCLIN K down-regulation with the PARP inhibitor overcomes ENZ resistance. Our findings identify CYCLIN K down-regulation as a key driver of IPA usage, hormonal therapy–induced AR-V expression, and castration resistance in PCa. These results suggest that hormonal therapy–induced AR-V expression and therapy resistance are vulnerable to PARP inhibitor treatment.
Glucocorticoids mediate transcriptome‐wide alternative polyadenylation: Potential mechanistic and clinical implications
Nguyen, Thanh Thanh L. , Liu, Duan , Gao, Huanyao , Ye, Zhenqing, Lee, Jeong‐Heon , Yu, Jia , Zhang, Lingxin , Wang, Liewei , Ördög, Tamás , Weinshilboum, Richard M. , Wang, Liewei , Ordog, Tamas , Weinshilboum, Richard M. , Nguyen, Thanh Thanh L. , Lee, Jeong-Heon , Liu, Duan , Wei, Lixuan

Mayo Clinic

Clinical and Translational Science | September 21, 2022 | Volume: 15 | Issue: 11 | Pages: 2758-2771

10.1111/cts.13402 | PMID 36128656 Get It

AbstractAlternative polyadenylation (APA) is a common genetic regulatory mechanism that generates distinct 3′ ends for RNA transcripts. Changes in APA have been associated with multiple biological processes and disease phenotypes. However, the role of hormones and their drug analogs in APA remains largely unknown. In this study, we investigated transcriptome‐wide the impact of glucocorticoids on APA in 30 human B‐lymphoblastoid cell lines. We found that glucocorticoids could regulate APA for a subset of genes, possibly by changing the expression of 142 RNA‐binding proteins, some with known APA‐regulating properties. Interestingly, genes with glucocorticoid‐mediated APA were enriched in viral translation‐related pathways, while genes with glucocorticoid‐mediated expression were enriched in interferon and interleukin pathways, suggesting that glucocorticoid‐mediated APA might result in functional consequences distinct from gene expression. For example, glucocorticoids, a pharmacotherapy for severe COVID‐19, were found to change the APA but not the expression of LY6E, an important antiviral inhibitor in coronavirus diseases. Glucocorticoid‐mediated APA was also cell‐type‐specific, suggesting an action of glucocorticoids that may be unique to immune regulation. We also observed evidence for genotype‐dependent glucocorticoid‐mediated APA (referred to as pharmacogenomic‐alterative polyadenylation quantitative trait loci), providing potential functional mechanisms for a series of common genetic variants that had previously been associated with immune disorders, but without a clear mechanism. In summary, this study reports a series of observations regarding the impact of glucocorticoids on APA, raising the possibility that this mechanism might have implications for both disease pathophysiology and drug therapy.
Nonalcoholic Fatty Liver Disease (Japanese Version)
Wang, Xiao‐Jing , Malhi, Harmeet

Mayo Clinic

Annals of Internal Medicine | September 20, 2022 | Volume: 169 | Issue: 9 | Pages: JITC65-JITC80

10.7326/istranslatedfrom_aitc201811060_japanese Get It

Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences
Nguyen, Thanh Thanh L. , Wang, Min , Liu, Duan , Bonilla, Hilda Mariana Gonzalez , Acker, Nancy, Murthy, Vishakantha , Shrivastava, Sanskriti , Desai, Viral , Burnett, John C. , Redfield, Margaret M. , Bailey, Kent R. , Weinshilboum, Richard M. , Pereira, Naveen L. , Iyer, Seethalakshmi , Gonzalez Bonilla, Hilda Mariana, Desai, Viral K , Redfield, Margaret, Pereira, Naveen L , Nguyen, Thanh Thanh L. , Wang, Min , Liu, Duan , Weinshilboum, Richard M.

Mayo Clinic

Circulation: Heart Failure | September 20, 2022 | Volume: 15 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.122.009629 | PMID 35656806 Get It

The “terminal line”: a novel sign for the identification of distal mesorectum end during TME for rectal cancer
Ghareeb, Waleed M. , Wang, Xiaojie , Zhao, Xiaozhen , Xie, Meirong, Shawki, Sherief , Chi, Pan , Chi, Pan , Emile, Sameh Hany

Mayo Clinic

Gastroenterology Report | September 16, 2022 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1093/gastro/goac050 | PMID 36157329 Get It

Abstract Background Although the clinical importance of complete, intact total mesorectal excision (TME) is the widely accepted standard for decreasing local recurrence of rectal cancer, the residual mesorectum still represents a significant component of resection margin involvement. This study aimed to use a visible intraoperative sign to detect the distal mesorectal end to ensure complete inclusion of the mesorectum and avoid unnecessary over-dissection. Methods The distal mesorectum end was investigated retrospectively through a review of 124 operative videos at the Union Hospital of Fujian Medical University (Fujian, China) and Cleveland Clinic (Ohio, USA) by two independent surgeons who were blinded to each other. Furthermore, 28 cadavers and 44 post-operative specimens were prospectively examined by hematoxylin and eosin (H&E) staining and Masson's staining to validate and confirm the findings of the retrospective part. Univariate and multivariate analyses were carried out to detect the independent factors that can affect the visualization of the distal mesorectal end. Results The terminal line (TL) is the distal mesorectal end of the transabdominal and transanal TME (taTME) and appears as a remarkable pearly white fascial structure extending posteriorly from 2 to 10 o'clock. Histopathological examination revealed that the fascia propria of the rectum merges with the presacral fascia at the TL, beyond which the mesorectum ends, with no further downward extension. In the retrospective observation, the TL was seen in 56.6% of transabdominal TME and 56.0% of taTME operations. Surgical approach and tumor distance from the anal verge were the independent variables that directly influenced the detection of the TL (P = 0.03 and P = 0.01). Conclusion The TL is a visible sign where the transabdominal TME should end and the taTME should begin. Recognition of the mesorectal end may impact the certainty of complete mesorectum inclusion. Further clinical trials are needed to confirm the preliminary findings.
Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia
Zhao, Na , Qiao, Wenhui , Li, Fuyao , Ren, Yingxue , Zheng, Jiaying , Martens, Yuka A. , Wang, Xusheng , Li, Ling , Liu, Chia‐Chen , Chen, Kai , Zhu, Yiyang , Ikezu, Tadafumi C. , Li, Zonghua , Meneses, Axel , Jin, Yunjung , Chen, Yixing , Sonustun, Berkiye , Job, Lucy , Smith, Madeleine L. , Xie, Manling , Liu, Yong , Umpierre, Anthony D. , Haruwaka, Koichiro , Quicksall, Zachary , Störz, Peter , Asmann, Yan W. , Wu, Long‐Jun , Bu, Guojun , Meneses, Axel D , Knight, Joshua A , Chen, Yixing , Bastea, Ligia , Linares, Cynthia , Sonustun, Berkiye , Job, Lucy , Smith, Madeleine L , Xie, Manling , Liu, Yong U , Umpierre, Anthony D , Haruwaka, Koichiro , Quicksall, Zachary S , Storz, Peter , Asmann, Yan W , Wu, Long-Jun , Bu, Guojun , Liu, Chia-Chen , Zhao, Na , Li, Fuyao , Zheng, Jiaying , Knight, Joshua A. , Bastea, Ligia I.

Mayo Clinic

Journal of Experimental Medicine | September 15, 2022 | Volume: 219 | Issue: 12 | Pages: No page available

10.1084/jem.20212479 | PMID 36107206 Get It

TREM2 is exclusively expressed by microglia in the brain and is strongly linked to the risk for Alzheimer’s disease (AD). As microglial responses modulated by TREM2 are central to AD pathogenesis, enhancing TREM2 signaling has been explored as an AD therapeutic strategy. However, the effective therapeutic window targeting TREM2 is unclear. Here, by using microglia-specific inducible mouse models overexpressing human wild-type TREM2 (TREM2-WT) or R47H risk variant (TREM2-R47H), we show that TREM2-WT expression reduces amyloid deposition and neuritic dystrophy only during the early amyloid seeding stage, whereas TREM2-R47H exacerbates amyloid burden during the middle amyloid rapid growth stage. Single-cell RNA sequencing reveals suppressed disease-associated microglia (DAM) signature and reduced DAM population upon TREM2-WT expression in the early stage, whereas upregulated antigen presentation pathway is detected with TREM2-R47H expression in the middle stage. Together, our findings highlight the dynamic effects of TREM2 in modulating AD pathogenesis and emphasize the beneficial effect of enhancing TREM2 function in the early stage of AD development.
Abstract A036: Surfaceome profiling of rhabdomyosarcoma reveals B7-H3 as a mediator of immune evasion
Lavoie, Roxane R. , Gargollo, Patricio C. , Baer, Emily , Phelps, Doris A., Charlesworth, M. Cristine , Hougthon, Peter J., Cheville, John C. , Granberg, Candace F. , Lucien, Fabrice , Ahmed, Mohamed E. , Kim, Yohan , Madden, Benjamin , Wang, Liguo , Dong, Haidong

Mayo Clinic

Clinical Cancer Research | September 15, 2022 | Volume: 28 | Issue: 18_Supplement | Pages: A036-A036

10.1158/1557-3265.sarcomas22-a036 Get It

Abstract Introduction: Pediatric rhabdomyosarcoma (RMS) is the most common soft tissue tumor in children, with nearly 20% of children presenting with locally aggressive and/or metastatic disease. Despite aggressive chemotherapy and radiotherapy, the 5-year overall survival rate is still less than 40%. In addition, resistance to chemotherapy remains the major cause of cancer-related mortality. Therefore, there is an unmet need to develop more effective and tolerable therapeutic strategies for the treatment of RMS. Our overall objective is to leverage transcriptomic and proteomic profiling methods to identify RMS-specific surface proteins targetable with immune-based therapies. Methods: To identify therapeutic targets, we performed cell-surface capture and mass spectrometry on fusion-positive (FP), fusion-negative (FN) RMS and normal skeletal muscle. Transcriptomic datasets of RMS tumor specimens and normal tissue were employed to identify high-confidence RMS-specific cell-surface proteins. Expression of immune checkpoint molecules was confirmed by flow cytometry, western blot and PCR. Paraffin-embedded tissue sections were used to determine protein expression and prognostic value in RMS patients. We developed an in vitro T-cell killing assay to assess the functional role of immune checkpoint molecules on the antitumor immune response. Results: Surfaceome profiling of RMS cells revealed unique protein signatures specific for each tumor type and normal tissue. We have identified 5061 cell-surface proteins in RMS and 31.6% of proteins were correctly located at the plasma membrane. By integrating proteomic and transcriptomic data, we have identified 30 and 38 proteins significantly overexpressed in fusion-negative and fusion-positive RMS respectively compared to normal muscle. We have identified the immune checkpoint molecule B7-H3 as cell-surface protein overexpressed in both RMS subtypes. Strong expression of B7-H3 was also observed in patient’s tumor specimens. Genetic deletion of B7-H3 gene in RMS cells was associated with higher antitumor immune response in tumor cells co-cultured with CD8+-T cells. No difference was observed in tumor cell proliferation and radioresistance. Conclusions: Through integrated transcriptomic and proteomic profiling, we have discovered B7-H3 as a key regulator of tumor immune-evasion in RMS. B7-H3 is a suitable immunotherapy target for the treatment of RMS. Further studies are warranted to elucidate underlying mechanisms of B7-H3 function in RMS. Citation Format: Roxane R. Lavoie, Fabrice Lucien, Patricio C. Gargollo, Mohamed E. Ahmed, Yohan Kim, Emily Baer, Doris Phelps, Cristine M. Charlesworth, Benjamin J. Madden, Liguo Wang, Peter J. Hougthon, John Cheville, Haidong Dong, Candace F. Granberg. Surfaceome profiling of rhabdomyosarcoma reveals B7-H3 as a mediator of immune evasion [abstract]. In: Proceedings of the AACR Special Conference: Sarcomas; 2022 May 9-12; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(18_Suppl):Abstract nr A036.